Cargando…

Evaluation of interleukin 8 polymorphisms (-251T/A and +781C/T) in patients with hepatocellular carcinoma: a meta-analysis

AIM OF THE STUDY: We reported the association between interleukin 8 (IL-8) polymorphisms (-251T/A and +781C/T) and hepatocellular carcinoma (HCC) risk in a meta-analysis. MATERIAL AND METHODS: Scopus, PubMed, Web of Science, and Cochrane Library databases were searched until 21 November 2020. The an...

Descripción completa

Detalles Bibliográficos
Autores principales: Aleagha, Omid Emami, Moeinzadeh, Forouzan, Shokouh, Seyedeh Farnaz Moeini, Doğan, Erkan, Sadeghi, Masoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527341/
https://www.ncbi.nlm.nih.gov/pubmed/34712829
http://dx.doi.org/10.5114/ceh.2021.109424
_version_ 1784586055877394432
author Aleagha, Omid Emami
Moeinzadeh, Forouzan
Shokouh, Seyedeh Farnaz Moeini
Doğan, Erkan
Sadeghi, Masoud
author_facet Aleagha, Omid Emami
Moeinzadeh, Forouzan
Shokouh, Seyedeh Farnaz Moeini
Doğan, Erkan
Sadeghi, Masoud
author_sort Aleagha, Omid Emami
collection PubMed
description AIM OF THE STUDY: We reported the association between interleukin 8 (IL-8) polymorphisms (-251T/A and +781C/T) and hepatocellular carcinoma (HCC) risk in a meta-analysis. MATERIAL AND METHODS: Scopus, PubMed, Web of Science, and Cochrane Library databases were searched until 21 November 2020. The analyses were performed by RevMan 5.3 software using odds ratios (ORs) and 95% confidence intervals (CIs). Also, the analysis of publication bias was performed by CMA 2.0 software. RESULTS: Searching databases/sources, five articles including ten studies were entered into the meta-analysis. The pooled ORs for -251T/A polymorphism were 1.07 (p = 0.55), 1.04 (p = 0.75), 1.31 (p = 0.24), 1.24 (p = 0.31), and 1.85 (p = 0.29) for allele, homozygote, heterozygote, recessive and dominant models, respectively. With regards to +781C/T polymorphism, the pooled ORs were 0.74 (p = 0.07), 0.53 (p = 0.03), 0.83 (p = 0.41), 0.75 (p = 0.19), and 0.57 (p = 0.02) for allele, homozygote, heterozygote, recessive, and dominant models, respectively. CONCLUSIONS: The findings of the meta-analysis showed a lack of significant association between IL-8 (-251T/A) polymorphism and the HCC risk, whereas the TT genotype of IL-8 (+781C/T) polymorphism had a protective role in HCC.
format Online
Article
Text
id pubmed-8527341
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-85273412021-10-27 Evaluation of interleukin 8 polymorphisms (-251T/A and +781C/T) in patients with hepatocellular carcinoma: a meta-analysis Aleagha, Omid Emami Moeinzadeh, Forouzan Shokouh, Seyedeh Farnaz Moeini Doğan, Erkan Sadeghi, Masoud Clin Exp Hepatol Original Paper AIM OF THE STUDY: We reported the association between interleukin 8 (IL-8) polymorphisms (-251T/A and +781C/T) and hepatocellular carcinoma (HCC) risk in a meta-analysis. MATERIAL AND METHODS: Scopus, PubMed, Web of Science, and Cochrane Library databases were searched until 21 November 2020. The analyses were performed by RevMan 5.3 software using odds ratios (ORs) and 95% confidence intervals (CIs). Also, the analysis of publication bias was performed by CMA 2.0 software. RESULTS: Searching databases/sources, five articles including ten studies were entered into the meta-analysis. The pooled ORs for -251T/A polymorphism were 1.07 (p = 0.55), 1.04 (p = 0.75), 1.31 (p = 0.24), 1.24 (p = 0.31), and 1.85 (p = 0.29) for allele, homozygote, heterozygote, recessive and dominant models, respectively. With regards to +781C/T polymorphism, the pooled ORs were 0.74 (p = 0.07), 0.53 (p = 0.03), 0.83 (p = 0.41), 0.75 (p = 0.19), and 0.57 (p = 0.02) for allele, homozygote, heterozygote, recessive, and dominant models, respectively. CONCLUSIONS: The findings of the meta-analysis showed a lack of significant association between IL-8 (-251T/A) polymorphism and the HCC risk, whereas the TT genotype of IL-8 (+781C/T) polymorphism had a protective role in HCC. Termedia Publishing House 2021-10-12 2021-09 /pmc/articles/PMC8527341/ /pubmed/34712829 http://dx.doi.org/10.5114/ceh.2021.109424 Text en Copyright © 2021 Clinical and Experimental Hepatology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/) )
spellingShingle Original Paper
Aleagha, Omid Emami
Moeinzadeh, Forouzan
Shokouh, Seyedeh Farnaz Moeini
Doğan, Erkan
Sadeghi, Masoud
Evaluation of interleukin 8 polymorphisms (-251T/A and +781C/T) in patients with hepatocellular carcinoma: a meta-analysis
title Evaluation of interleukin 8 polymorphisms (-251T/A and +781C/T) in patients with hepatocellular carcinoma: a meta-analysis
title_full Evaluation of interleukin 8 polymorphisms (-251T/A and +781C/T) in patients with hepatocellular carcinoma: a meta-analysis
title_fullStr Evaluation of interleukin 8 polymorphisms (-251T/A and +781C/T) in patients with hepatocellular carcinoma: a meta-analysis
title_full_unstemmed Evaluation of interleukin 8 polymorphisms (-251T/A and +781C/T) in patients with hepatocellular carcinoma: a meta-analysis
title_short Evaluation of interleukin 8 polymorphisms (-251T/A and +781C/T) in patients with hepatocellular carcinoma: a meta-analysis
title_sort evaluation of interleukin 8 polymorphisms (-251t/a and +781c/t) in patients with hepatocellular carcinoma: a meta-analysis
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527341/
https://www.ncbi.nlm.nih.gov/pubmed/34712829
http://dx.doi.org/10.5114/ceh.2021.109424
work_keys_str_mv AT aleaghaomidemami evaluationofinterleukin8polymorphisms251taand781ctinpatientswithhepatocellularcarcinomaametaanalysis
AT moeinzadehforouzan evaluationofinterleukin8polymorphisms251taand781ctinpatientswithhepatocellularcarcinomaametaanalysis
AT shokouhseyedehfarnazmoeini evaluationofinterleukin8polymorphisms251taand781ctinpatientswithhepatocellularcarcinomaametaanalysis
AT doganerkan evaluationofinterleukin8polymorphisms251taand781ctinpatientswithhepatocellularcarcinomaametaanalysis
AT sadeghimasoud evaluationofinterleukin8polymorphisms251taand781ctinpatientswithhepatocellularcarcinomaametaanalysis